


Amendments to the claims:

1. (Currently amended) A method for treating a subject with an allergic condition, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) below:



wherein:

R^1 is hydrogen, azido, halogen, C_{1-5} alkoxy, hydroxy, C_{1-5} alkyl, C_{2-5} alkenyl, cyano, nitro, R^7R^8N , C_{2-8} acyl, $R^9OC=O$, $R^{10}R^{11}NC=O$, or $R^{10}R^{11}NSO_2$; or R^1 is taken together with W as described below;

R^2 is hydrogen, halogen, C_{1-5} alkoxy, C_{1-5} alkyl, C_{2-5} alkenyl, C_{1-5} haloalkyl, cyano, or $R^{48}R^{49}N$;

alternatively, R^1 and R^2 can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;

each of R^3 and R^4 is independently hydrogen or C_{1-5} alkyl;

each of R^5 and R^6 is independently hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{1-5} alkoxy, C_{1-5} alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl;

alternatively, R^5 and R^6 can be taken together to form an optionally substituted 6-membered carbocyclic ring, ~~5- to 7- membered carbocyclic or heterocyclic ring~~, which ring may be unsaturated or aromatic, and may be optionally substituted with between one and three substituents independently selected from halo, cyano, amino, nitro, R^{40} , $R^{40}O-$, $R^{40}S-$, $R^{40}O(C_{1-5} alkylene)-$, $R^{40}O(C=O)-$, $R^{40}(C=O)-$, $R^{40}(C=S)-$, $R^{40}(C=O)O-$,

$R^{40}O(C=O)(C=O)-$, $R^{40}SO_2$, $NHR^{62}(C=NH)-$, $NHR^{62}SO_2-$, and $NHR^{62}(C=O)-$;

R^{40} is H, C₁₋₅ alkyl, C₂₋₅ alkenyl, phenyl, benzyl, phenethyl, C₁₋₅ heterocyclyl, (C₁₋₅ heterocyclyl)C₁₋₅ alkylene, amino, or mono- or di(C₁₋₅ alkyl)amino, or $R^{58}OR^{59}-$, wherein R^{58} is H, C₁₋₅ alkyl, C₂₋₅ alkenyl, phenyl, benzyl, phenethyl, C₁₋₅ heterocyclyl, or (C₁₋₅ heterocyclyl)C₁₋₆ alkylene and R^{59} is C₁₋₅ alkylene, phenylene, or divalent C₁₋₅ heterocyclyl; and

R^{62} can be H in addition to the values for R^{40} ;

R^7 is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, naphthyl, C₁₋₅ heterocyclyl, C₂₋₈ acyl, aroyl, $R^{27}OC=O$, $R^{28}R^{29}NC=O$, $R^{27}SO$, $R^{27}SO_2$, or $R^{28}R^{29}NSO_2$;

R^8 is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, or C₁₋₅ heterocyclyl; alternatively, R^7 and R^8 can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

R^9 is C₁₋₅ alkyl, phenyl, naphthyl, or C₁₋₅ heterocyclyl;

R^{21} is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, naphthyl, C₁₋₅ heterocyclyl, C₂₋₈ acyl, aroyl, $R^{30}OC=O$, $R^{31}R^{32}NC=O$, $R^{30}SO$, $R^{30}SO_2$, or $R^{31}R^{32}NSO_2$;

R^{22} is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, or C₁₋₅ heterocyclyl; alternatively, R^{21} and R^{22} can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of R^{23} , R^{26} , R^{27} , R^{30} , R^{33} , R^{44} , R^{45} , and R^{50} is C₁₋₅ alkyl, phenyl, naphthyl, or C₁₋₅ heterocyclyl;


R^{24} is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, naphthyl, C₁₋₅ heterocyclyl, C₂₋₈ acyl, aroyl, $R^{33}OC=O$, $R^{34}R^{35}NC=O$, $R^{33}SO$, $R^{33}SO_2$, or $R^{34}R^{35}NSO_2$;

R^{25} is hydrogen, C₁₋₅ alkyl, C₃₋₅ alkenyl, phenyl, or C₁₋₅ heterocyclyl; alternatively, R^{24} and R^{25} can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;


each of R^{10} and R^{11} is independently hydrogen, C₁₋₅ alkyl, C₂₋₅ alkenyl, phenyl, or C₁₋₅ heterocyclyl;

- alternatively, R^{10} and R^{11} or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of R^{28} , R^{29} , R^{31} , R^{32} , R^{34} , R^{35} , R^{46} , R^{47} , R^{51} and R^{52} is independently hydrogen, C_{1-5} alkyl, phenyl, or C_{1-5} heterocyclyl;
- alternatively, R^{28} and R^{29} , R^{31} and R^{32} , R^{34} and R^{35} , R^{46} and R^{47} , or R^{51} and R^{52} , independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- n is 1 or 2;
- G represents C_{3-6} alkenediyl or C_{3-6} alkanediyl, optionally substituted with hydroxy, halogen, C_{1-5} alkyl, C_{1-5} alkoxy, oxo, hydroximino, CO_2R^{60} , $R^{60}R^{61}NCO_2$, (L)- C_{1-4} alkylene-, (L)- C_{1-5} alkoxy, N_3 , or [(L)- C_{1-5} alkylene]amino;
- each of R^{60} and R^{61} is independently hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, benzyl, phenethyl, or C_{1-5} heterocyclyl; alternatively R^{60} and R^{61} , can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- L is amino, mono- or di- C_{1-5} alkylamino, pyrrolidinyl, morpholinyl, piperidinyl, homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with C_{1-5} alkyl, benzyl, C_{2-5} acyl, C_{1-5} alkylsulfonyl or C_{1-5} alkylloxycarbonyl;
- X is nitrogen or $R^{12}C$;
- Y is nitrogen or $R^{13}C$;
- Z is nitrogen or $R^{14}C$;
- R^{12} is hydrogen, halogen, C_{1-5} alkoxy, C_{1-5} alkyl, C_{2-5} alkenyl, cyano, nitro, $R^{21}R^{22}N$, C_{2-8} acyl, C_{1-5} haloalkyl, C_{1-5} heterocyclyl, (C_{1-5} heterocyclyl) C_{1-5} alkylene, $R^{23}OC=O$, $R^{23}O(C=O)NH-$, $R^{23}SO$, $R^{22}NHCO-$, $R^{22}NH(C=O)NH-$, $R^{23}(C_{1-4} \text{ alkylene})NHCO-$, $R^{23}SO_2$, or $R^{23}SO_2NH-$;
- R^{13} is hydrogen, halogen, C_{1-5} alkoxy, C_{1-5} alkyl, C_{2-5} alkenyl, cyano, nitro, $R^{42}R^{43}N$, C_{2-8} acyl, C_{1-5} haloalkyl, C_{1-5} heterocyclyl, (C_{1-5} heterocyclyl) C_{1-5}

- alkylene, $R^{44}OC=O$, $R^{44}O(C=O)NH-$, $R^{44}SO$, $R^{43}NHCO-$, $R^{43}NH(C=O)NH-$, $R^{44}(C_{1-4} \text{ alkylene})NHCO-$, $R^{44}SO_2$, or $R^{44}SO_2NH-$;
- R^{14} is hydrogen, halogen, C_{1-5} alkoxy, C_{1-5} alkyl, C_{2-5} alkenyl, cyano, nitro, $R^{24}R^{25}N$, C_{2-8} acyl, C_{1-5} haloalkyl, C_{1-5} heterocyclyl, $(C_{1-5} \text{ heterocyclyl})C_{1-5}$ alkylene, $R^{26}OC=O$, $R^{26}O(C=O)NH-$, $R^{26}SO$, $R^{25}NHCO-$, $R^{25}NH(C=O)NH-$, $R^{26}(C_{1-4} \text{ alkylene})NHCO-$, $R^{26}SO_2$, or $R^{26}SO_2NH-$;
- alternatively, R^{12} and R^{13} or R^{12} and R^2 or R^{13} and R^{14} can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;
- Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen, C_{1-5} alkoxy, C_{1-5} alkyl, C_{2-5} alkenyl, cyano, azido, nitro, $R^{15}R^{16}N$, $R^{17}SO_2$, $R^{17}S$, $R^{17}SO$, $R^{17}OC=O$, $R^{15}R^{16}NC=O$, C_{1-5} haloalkyl, C_{1-5} haloalkoxy, C_{1-5} haloalkylthio, and C_{1-5} alkylthio;
- R^{15} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, benzyl, C_{1-5} heterocyclyl, C_{2-8} acyl, aroyl, $R^{53}OC=O$, $R^{54}R^{55}NC=O$, $R^{53}S$, $R^{53}SO$, $R^{53}SO_2$, or $R^{54}R^{55}NSO_2$;
- R^{16} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, benzyl, or C_{1-5} heterocyclyl; alternatively, R^{15} and R^{16} can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of R^{17} and R^{53} is C_{1-5} alkyl, phenyl, or C_{1-5} heterocyclyl;
- each of R^{54} and R^{55} is independently hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, phenyl, benzyl, or C_{1-5} heterocyclyl;
- alternatively, R^{54} and R^{55} can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- W represents SO_2 , $C=O$, CHR^{20} , or a covalent bond; or W and R^1 , taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:



(I)(a)



(I)(b)

wherein X_a is O, S, or N; and X_b is O, S or SO_2 ;

R^{20} is hydrogen, C_{1-5} alkyl, phenyl, benzyl, naphthyl, or C_{1-5} heterocyclyl;

R^{42} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, naphthyl, C_{1-5} heterocyclyl, C_{2-8} acyl, aroyl, $R^{45}OC=O$, $R^{46}R^{47}NC=O$, $R^{45}SO$, $R^{45}SO_2$, or $R^{46}R^{47}NSO_2$;

R^{43} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, or C_{1-5} heterocyclyl;

alternatively, R^{42} and R^{43} can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

R^{44} is C_{1-5} alkyl, C_{2-5} alkenyl, phenyl, naphthyl, or C_{1-5} heterocyclyl;

R^{48} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, naphthyl, C_{1-5} heterocyclyl, C_{2-8} acyl, aroyl, $R^{50}OC=O$, $R^{51}R^{52}NC=O$, $R^{50}SO$, $R^{50}SO_2$, or $R^{51}R^{52}NSO_2$;

R^{49} is hydrogen, C_{1-5} alkyl, C_{3-5} alkenyl, phenyl, or C_{1-5} heterocyclyl;

alternatively, R^{48} and R^{49} can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and

wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano, C_{1-5} alkyl, C_{1-5} alkoxy, $-COOH$, C_{2-6} acyl, $[di(C_{1-4} \text{ alkyl})amino]C_{2-5}$ alkylene, $[di(C_{1-4} \text{ alkyl})amino]C_{2-5}$ alkyl-NH-CO-, and C_{1-5} haloalkoxy;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. (Previously presented) A method of claim 1, wherein each of R³ and R⁴ is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen, C₁₋₅ alkyl, cyano, nitro, R¹⁵R¹⁶N, CF₃ and OCF₃; R¹² is hydrogen, R²³SO, or R²³SO₂; R¹³ is hydrogen, R⁴⁴SO, or R⁴⁴SO₂; R¹⁴ is hydrogen, halogen, C₁₋₅ alkoxy, C₁₋₅ alkyl, cyano, nitro, or R²⁴R²⁵N; and G is C₃ alkanediyl, optionally substituted with hydroxy, (L)-C₁₋₅ alkyloxy-, or (L)-C₁₋₅ alkylamino.

3. (Previously presented) A method of claim 2, wherein Ar is phenyl.

4. (Canceled)

5. (Canceled)

6. (Currently amended) A method of claim 1, wherein said compound is selected from :

~~1-(3-(4-Chloro-phenyl)-1-[3-[4-(2-fluoro-phenyl)-piperazin-1-yl]-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone;~~

~~1-(3-(4-Chloro-phenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone;~~

~~1-(3-(4-Chloro-phenyl)-1-[2-methoxy-3-(4-o-tolyl-piperazin-1-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethanone;~~

~~1-[1-[2-Hydroxy-3-[4-(2-hydroxy-phenyl)-piperazin-1-yl]-propyl]-3-(4-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~

~~1-[1-[2-Hydroxy-3-(4-o-tolyl-piperazin-1-yl)-propyl]-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~

~~2-(4-[3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl]-piperazin-1-yl)-benzonitrile;~~

~~1-[3-(3,4-Dichloro-phenyl)-pyrazol-1-yl]-3-(4-o-tolyl-piperazin-1-yl)-propan-2-ol;~~

~~1-[1-[2-(2-Piperazin-1-yl-ethylamino)-3-(4-o-tolyl-piperazin-1-yl)-propyl]-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~

~~1-[3-[4-(2-Cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl]-3-(4-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;~~
~~1-[3-[4-(2-Cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl]-3-(4-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;~~
~~Carbamic acid 1-[5-carbamoyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-ylmethyl]-2-[4-(2-cyano-phenyl)-piperazin-1-yl]-ethyl ester;~~
~~1-[3-(3-Amino-4-chloro-phenyl)-1-[2-hydroxy-3-(4-o-tolyl-piperazin-1-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~
~~(R)-1-[3-(4-Bromo-phenyl)-1-[3-[4-(5-chloro-2-methyl-phenyl)-piperazin-1-yl]-2-hydroxy-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~
~~2-[4-[3-[5-Acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-fluoro-propyl]-piperazin-1-yl]-benzonitrile;~~
~~[3-(4-Chloro-3-methyl-phenyl)-1-[3-[4-(2-cyano-phenyl)-piperazin-1-yl]-2-hydroxy-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester;~~
~~5-Methanesulfonyl-1-[3-[4-(2-nitro-phenyl)-piperazin-1-yl]-propyl]-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;~~
~~1-[3-Chloro-2-[4-[3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl]-piperazin-1-yl]-phenyl]-urea;~~
~~1-[3-[4-(2-Chloro-6-methanesulfonylamino-phenyl)-piperazin-1-yl]-propyl]-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-sulfonic acid amide;~~
~~N-[3-Chloro-2-[4-[2-hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl]-piperazin-1-yl]-phenyl]-methanesulfonamide;~~
~~1-[4-(2,6-Dinitro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol;~~
~~2-[4-[2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl]-piperazin-1-yl]-3-methanesulfonylamino-benzoic acid methyl ester;~~

~~1-[3-[4-(1,1-Dioxo-1H-1H-benzo[d]isothiazol-3-yl)-piperazin-1-yl]-propyl]-5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;~~

~~1-[1-[3-[4-(6-Chloro-benzothiazol-2-yl)-piperazin-1-yl]-2-hydroxy-propyl]-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;~~
and

~~1-[1-[3-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl]-2-hydroxy-propyl]-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone.~~

7. (Canceled)

8. (Previously presented) A method of claim 1, wherein said pharmaceutical composition is formulated in a dosage amount appropriate for the treatment of an allergic condition.
9. (New) A method of claim 1, wherein said condition is asthma.
10. (New) A method of claim 2, wherein said condition is asthma.
11. (New) A method of claim 3, wherein said condition is asthma.
12. (New) A method of claim 7, wherein said condition is asthma.